By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
Rusfertide Cuts Phlebotomies by 77% in Polycythemia Vera
by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]
Phase 3 Clinical Trial for Polycythemia Vera
Unfortunately for some polycythemia vera (PV) patients, current treatment options may not be fully effective or well-tolerated and may cause serious side effects. But a promising investigational treatment is currently being clinically evaluated. Rusfertide, also known as PTG-300, is an investigational new drug designed to slow the release of iron into the bone marrow. The […]
MPN Clinical Trials, 2022 Update
MPN Clinical Trial update with Dr. Abu-Zeinah, from ASH 2021 by David Wallace TRANSCRIPT | MPN Clinical Trials, 2022 Update David Wallace: Hello, I’m David Wallace, founder of PV Reporter and our nonprofit organization MPN Cancer Connection. And your host for today’s program, the American Society of Hematology 2021 update, is Dr. Ghaith Abu-Zeinah from […]
